Multiple Sclerosis – Induced Multiple Sclerosis Mouse Models
Test novel compounds targeting Multiple Sclerosis with the support of our services in de- and re-myelinating multiple sclerosis mouse models
Multiple Sclerosis Mouse Models Key Characteristics:
Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating, and neurodegenerative disease. The pathological hallmark of MS is the formation of demyelinating lesions in the brain and spinal cord. The core neuropathology of MS is the loss of oligodendrocytes and myelin sheaths, leading to axonal damage and neuroinflammation.
InnoSer offers unique preclinical contract research services using several multiple sclerosis mouse models that show pathological de- and re-myelination. In the Cuprizone mouse model of multiple sclerosis, Cuprizone induces oligodendrocyte death and progressive and reversible myelination, recapitulating the de- and re-myelinating pathophysiology of human MS, representing a model of acute and chronic de- and re-myelination of corpus callosum. Similarly, the lysolecithin-induced mouse model of demyelination offers a rapid model with quick, reproducible and wide-spread demyelination in the central nervous system (CNS). Using the lysolecithin model, depending on the injection site, both de- and re-myelienation can be studied in different anatomical regions of mouse CNS.
✓ Lysolecithin-induced demyelination model with focal injection
✓ Complementary in vitro (e.g., oligodendrocyte precursor cells) and ex vivo (using brain slices) services
✓ Complementary PK/PD profiling services.
As a preclinical neurology CRO, InnoSer offers well-established and clinically relevant multiple sclerosis mouse models, complemented with standardized study protocols to ensure consistency and reproducibility of your results. In addition, InnoSer offers research services using the Experimental Autoimmune Encephalomyelitis (EAE) mouse model of Multiple Sclerosis. While Cuprizone and Lysolecithin models enable you to test efficacy of compounds directed at remyelination, the EAE mouse model allows you to focus on the inflammatory component of MS. However, as all models have their unique characteristics, we recommend discussing your study setup in close collaboration with our experts.
InnoSer’s research network comprises scientific experts working on multiple sclerosis, offering you the possibility to consult your compound’s MOA in-depth. By choosing InnoSer as your preclinical multiple sclerosis CRO, you will work alongside expert study directors who take collaborative approach for your study. With flexible and fast study start times you can perform your multiple sclerosis research at an accelerated pace.
Your Neurology Research Starts Here.
Choose the Right Model for Your Research with Confidence
Multiple Sclerosis Mouse Models Sample Data
Functional demyelination was assessed at the end of the 6-week cuprizone exposure period using Visual Evoked Potential (VEP) recordings, evaluating both latency (conduction of action potentials) and amplitude (indicating axonal injury or persistent demyelination).
(A) VEP latency was significantly prolonged in cuprizone-treated mice compared with untreated controls, indicating impaired signal conduction through the visual pathway as a consequence of demyelination (**p < 0.0001 vs. baseline; Two-way ANOVA with Dunnett’s multiple comparisons test; N = 10).
(B) VEP amplitude was higher at week 6 as compared to baseline but remained the same between cuprizone-treated and control animals, demonstrating no axonal loss (Two-way ANOVA with Dunnett’s multiple comparisons test; N = 10). Data are represented as mean ± SD
Multiple Sclerosis Mouse Models Readouts
Biological Readouts
Test the efficacy of your treatments with the following biological readouts:
- IHC: Myelin, immune response, astrocytes, de/remyelination (MBP, PLP), Inflammation (macrophages, T- and B-cells, microglia, astrocytes)
- mRNA or protein of inflammatory mediators, receptors, etc.
- Complementary in vitro (e.g., microglial activation, phagocytosis, oligodendrocyte precursor cells [OPCs] differentiation, microfiber myelination) and ex vivo (using cultured brain slides) screening services.
- Blood collection for PK/PD profiling
The People Behind Your Research
Sofie Carmans, PhD
Principal Scientist Neurology
Hasselt University/BIOMED
As part of a joint initiative to advance preclinical MS research, InnoSer works together with researchers from BIOMED, who focus on immunological mechanisms, myelination, and damage processes in the brain during MS.
Frequently Asked Questions
What multiple sclerosis mouse models does InnoSer offer for preclinical efficacy studies?
InnoSer offers three complementary preclinical MS mouse models, each capturing a distinct pathological aspect of the disease. Importantly, each mouse model of multiple sclerosis addresses a distinct aspect of the disease pathophysiology; choosing the right one depends on your compound’s mechanism of action.
The cuprizone-induced mouse model of demyelination is the gold standard mouse model to study effects of novel remyelinating compounds, mostly targeting oligodendrocyte precursor cells (OPCs), as well as neuroprotective strategies and innate neuroinflammation-targeting approaches. Accordingly, cuprizone diet (0.4%) in standard chow induces widespread, reproducible demyelination of the corpus callosum and associated white and grey matter, driving selective oligodendrocyte apoptosis followed by spontaneous OPC-driven remyelination (washout period where no cuprizone is added to chow). At InnoSer, the cuprizone-induced mouse model of demyelination is available in both acute (6-week) and chronic (12-week) dosing designs. Learn more about the readouts (including VEP as a highly translational readout of functional remyelination) and view InnoSer’s full validation datasets on our cuprizone-induced mouse model webpage here.
In contrast to the cuprizone mouse model, the EAE mouse model is standardly used model for studying T and B lymphocyte-driven neuroinflammation and immune-mediated demyelination, mimicking the immune-mediated mechanisms that take place in the human course of multiple sclerosis. Therefore, the EAE mouse model arises as an appropriate mouse model for immunomodulatory compounds, anti-inflammatory and disease-modifying therapeutics for multiple sclerosis. Learn more about the readouts and view InnoSer’s full validation datasets on EAE mouse model webpage here.
Lastly, the lysolecithin-induced focal demyelination model (offered in collaboration with Hasselt University, see our press release for details) produces a discrete, anatomically targeted demyelinating lesion via direct stereotaxic injection of lysophosphatidylcholine into CNS white matter. This procedure produces a well-characterised demyelinating injury consisting principally of macrophage and microglial infiltration and activation, reactive astrogliosis, axonal injury, and OPC proliferation and migration.
Complementary in vitro (oligodendrocyte precursor cell differentiation assays) and ex vivo services (cultured brain slices) can be run alongside or independently of the in vivo MS models, offered in collaboration with the University of Hasselt.
Contact our team to discuss which model or combination best fits your compound’s mechanism.
Discover Other Relevant Neurological Disease Models
Discover InnoSer’s Latest Research
![Translational Neuroscience: Comprehensive longitudinal profiling of the Tau[P301S] female vs male mice](https://www.innoserlaboratories.com/wp-content/uploads/2026/06/Female-TauP301S-mice-show-early-spontaneous-hyperactivity-in-automated-home-cages-PhenoTyperTM-229375_1080x323.png)
Translational Neuroscience: Comprehensive longitudinal profiling of the Tau[P301S] female vs male mice
In this month’s newsletter, we highlight and build upon our knowledge working with the Tau[P301S] mouse model (originally described by Allen et al., 2002), and its applicability in preclinical research.Female and male...
Clinically relevant biomarker panels for comprehensive efficacy studies in Alzheimer’s Disease mouse models
InnoSer's validated Alzheimer's disease (AD) mouse models are equipped with translationally relevant biomarker readout panels — spanning amyloid-beta (Aβ) species, phosphorylated Tau isoforms, and the early, sensitive hallmark of neurodegeneration, neurofilament light...
![Proven Compound Susceptible Tau[P301S] Mouse Model for Preclinical Proof of Concept](https://www.innoserlaboratories.com/wp-content/uploads/2026/03/Proven-Compound-susceptible-TauP301S-mouse-model-for-preclinical-proof-of-concept--1080x675.png)
Proven Compound Susceptible Tau[P301S] Mouse Model for Preclinical Proof of Concept
The Tau[P301S] mouse remains one of the most established in vivo models for evaluating therapeutics targeting tauopathies including Alzheimer's disease and frontotemporal dementia (FTD). Presented at AD/PD 2025 in Vienna, this poster provides comprehensive...
Home-Cage Behavior Discriminates Neurodegeneration Models from Healthy Aging Mice
Distinguishing pathological neurodegeneration from normal biological aging is a fundamental challenge in preclinical neuroscience. Presented at AD/PD 2023 in Gothenburg, this poster — developed in collaboration with Sylics and VU University Amsterdam — establishes a...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com